55 completed. 55 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 55 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of Swift Microwave Device for Onychomycosis Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail | Phase 1 / Phase 2 | Completed | Mediprobe Research Inc. | 39 | 2023-03-27 | 2024-11-18 |
| A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail BB2603-1, BB2603-3, BB2603-10 - Distal Subungual Onychomycosis, Fungal Infection | Phase 2 | Completed | Blueberry Therapeutics | 111 | 2021-03-22 | 2023-08-01 |
| A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor DBI-002 probiotic gel, Aqueous gel - Tinea Versicolor | Phase 2 | Completed | DermBiont, Inc. | 34 | 2021-03-16 | 2025-07-03 |
| A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream - Tinea Pedis | Phase 2 | Completed | Therapeutics, Inc. | 240 | 2019-03-15 | 2021-10-28 |
| A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis Janthinobacterium lividum - Tinea Pedis | Phase 2 | Completed | DermBiont, Inc. | 12 | 2019-02-19 | 2025-06-17 |
| Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 88 | 2018-09-17 | 2023-07-07 |
| Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel voriconazole gel once daily, voriconazole gel twice daily, placebo - Tinea Versicolor | Phase 2 | Completed | Sara Botros | 30 | 2018-02-15 | 2019-10-01 |
| Clinical Assessment of Itraconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel itraconazole gel once daily, itraconazole gel twice daily, placebo - Tinea Versicolor | Phase 2 | Completed | Sara Botros | 30 | 2018-02-15 | 2019-10-01 |
| Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan Fosravuconazole, Itraconazole - Mycetoma | Phase 2 | Completed | Drugs for Neglected Diseases | 104 | 2017-05-09 | 2024-07-18 |
| Three-Arm Trial of Novel Treatment for Tinea Pedis Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride - Tinea Pedis | Phase 2 | Completed | South End Skin Care | 90 | 2017-01-03 | 2017-10-06 |
| CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Amphotericin B - Candidiasis, Chronic Mucocutaneous | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 4 | 2016-09-27 | 2024-08-07 |
| Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot Nitric Oxide, Water - Tinea Pedis | Phase 2 | Completed | Nitric Solutions Inc. | 20 | 2016-08-13 | 2019-09-20 |
| SB208 for the Treatment of Tinea Pedis SB208 2%, SB208 4%, SB208 16% - Tinea Pedis | Phase 2 | Completed | Novan, Inc. | 222 | 2016-07-19 | 2019-01-10 |
| Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail HTS-519 Insert - Onychomycosis | Phase 2 | Completed | Hallux, Inc. | 30 | 2016-07-01 | 2021-11-02 |
| Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study NVXT topical, Placebo (Vehicle) Topical - Onychomycosis | Phase 2 | Completed | Sun Pharmaceutical Industries, Inc. | 184 | 2016-03-21 | 2018-12-20 |
| Design and Clinical Evaluation of a School Meal With Deworming Properties Ujiplus, Albendazole, uji - Helminthiasis, Tinea Capitis | Phase 2 / Phase 3 | Completed | Kenya Medical Research Institute | 326 | 2015-05-01 | 2016-09-07 |
| A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail VT-1161, Placebo - Onychomycosis | Phase 2 | Completed | Viamet | 259 | 2015-02-17 | 2020-11-04 |
| Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail. PD P 506 A - Onychomycosis | Phase 2 | Completed | photonamic GmbH & Co. KG | 25 | 2015-01-01 | 2017-09-19 |
| Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail NVXT Solution, Vehicle of test product - Onychomycosis | Phase 2 | Completed | Sun Pharmaceutical Industries, Inc. | 47 | 2014-12-01 | 2018-09-19 |
| Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis Dapaconazole, Ketoconazole - Tinea Pedis | Phase 2 | Completed | Gilberto De Nucci | 60 | 2014-07-01 | 2016-07-07 |
Showing 20 of 55. Sign in to see all of them.
Onychomycosis (30) · Tinea Pedis (13) · Mycoses (6) · Blastomycosis (3) · Communicable Diseases (3) · Histoplasmosis (3) · Rare Diseases (3) · Sporotrichosis (3) · Tinea (3) · Tinea Versicolor (3) · Immune System Diseases (2) · Tinea Cruris (2) · Anemia (1) · Candidiasis, Chronic Mucocutaneous (1) · Coccidioidomycosis (1)
Bacterial Infections and Mycoses (55) · Skin Diseases, Infectious (55) · Skin and Connective Tissue Diseases (55) · Infections (54) · Skin Diseases (54) · Mycoses (49) · Tinea (43) · Nail Diseases (30) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (13) · Skin Manifestations (13) · Foot Dermatoses (12) · Foot Diseases (12) · Pruritus (12)
Terbinafine (5) · tavaborole (5) · Itraconazole (4) · 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2) · Fluconazole (2) · Nitric Oxide (2) · VT-1161 (2) · Albendazole (1) · Amphotericin B (1) · BANG polymer gel (1) · Econazole (1) · Exercise (1) · Ketoconazole (1) · Miconazole (1) · Nitrogen (1)
Pfizer (7) · Nitric BioTherapeutics, Inc (4) · DermBiont, Inc. (2) · National Center for Research Resources (NCRR) (2) · Sara Botros (2) · Sun Pharmaceutical Industries, Inc. (2) · Topica Pharmaceuticals (2) · Viamet (2) · Abeona Therapeutics, Inc (1) · Almirall, S.A. (1) · AmDerma (1) · Bayer (1) · Blueberry Therapeutics (1) · Celtic Pharma Development Services (1) · Dow Pharmaceutical Sciences (1)
United States (26) · Canada (8) · Germany (4) · Mexico (4) · Dominican Republic (2) · Egypt (2) · Brazil (1) · Czechia (1) · El Salvador (1) · Iceland (1) · India (1) · Panama (1) · Poland (1) · Puerto Rico (1) · Saint Kitts and Nevis (1)
William Dismukes (3) · Sara R Botros, bachelor of clinical pharmacy (2) · Aditya Gupta, MD,PhD (1) · Ahmed Fahal, Prof (1) · Alexandra Freeman, MD (1) · Alicia Barba, MD (1) · Alicia Bucko, DO (1) · Andrej Spec, MD (1) · Bernard Goffe, MD (1) · Boni Elewski, MD (1) · Brock McConnehey,, DO (1) · Carl Schanbacher, MD (1)
PMID 21967490, PMID 23377392, PMID 30526582, PMID 32421854, PMID 32457106, PMID 35699443, PMID 38440302, PMID 39098321, PMID 39624747, PMID 40433693
2008 (1), 2009 (1)